## S4 Table. Yellow fever and meningococcal A vaccine seroconversion at 28 days post-immunization by EED and GH status measured by ELISA (N = 300 unless otherwise noted).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Biomarker and quartile** | **No. of infants** **(% of total)** | **No. (%) seroconverted to YFV (NT ≥ fourfold increase)** | **Trend test****P-value** | **No. (%) seroconverted to MenAV (SBA ≥ fourfold increase)** | **Trend test****P-value** |
| **I-FABP—quartiles (cutoffs in pg/mL)** |
| **1** (< 504.2) | 75 (25.0) | 49 (65.3) | 0.224 | 69 (92) | 1.000 |
| **2** (< 820.4) | 75 (25.0) | 51 (68.0) | 74 (98.67) |
| **3** (< 1200.3) | 75 (25.0) | 46 (61.3) | 71 (94.67) |
| **4** (> 1200.3) | 75 (25.0) | 58 (77.3) | 70 (93.33) |
| **sCD14—quartiles (cutoffs in ng/mL)** |
| **1** (< 1297.2) | 75 (25.2) | 49 (65.3) | 0.724 | 73 (97.33) | 0.352 |
| **2** (< 1615.7) | 74 (24.8) | 52 (70.3) | 69 (93.24) |
| **3** (< 1867.2) | 75 (25.2) | 51 (68.0) | 71 (94.67) |
| **4** (> 1867.2) | 74 (24.8) | 51 (68.9) | 69 (93.24) |
| **IGF-1—quartiles (cutoffs in ng/mL)0** |
| **1** (< 12.2) | 76 (25.3) | 41 (54.0) | **0.002** | 72 (94.74) | 0.461 |
| **2** (< 19.7) | 77 (25.3) | 55 (72.4) | 74 (97.37) |
| **3** (< 27.8) | 74 (24.7) | 48 (64.9) | 69 (93.24) |
| **4** (> 27.8) | 75 (24.7) | 60 (81.1) | 69 (93.24) |
| **FGF21—quartiles (cutoffs in pg/mL)** |
| **1** (< 92.4) | 75 (25.0) | 49 (65.3) | 0.912 | 70 (93.33) | 0.646 |
| **2** (< 163.6) | 75 (25.0) | 54 (72.0) | 73 (97.33) |
| **3** (< 345.7) | 75 (25.0) | 50 (66.7) | 72 (96) |
| **4** (> 345.7) | 75 (25.0) | 51 (68.0) | 69 (92) |

*Abbreviations:* CI, confidence interval; FGF21, fibroblast growth factor 21; I-FABP, intestinal fatty acid–binding protein; IGF-1, insulin-like growth factor 1; NT, neutralizing antibody titer; SBA, serum bactericidal assay; sCD14, soluble cluster of differentiation 14.

0 n = 298 for sCD14.

1 n = 152 for GLP-2.